In metastatic colorectal cancer (mCRC), KRAS is the only validated biomarker used to select patients for administration of epidermal growth factor receptor (EGFR)-targeted therapies. To identify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback